CTRI/2018/04/013495已完成未知
Association of CYP3A5 polymorphism with trough levels of tacrolimus and graft outcomes in Indian renal transplant recipients.
Seth GS Medical College and KEM Hospital0 个研究点目标入组 150 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Renal allograft recipients on tacrolimus therapy [for at least three months] attending transplant clinic
- •Willing to give written, informed consent
排除标准
- •Subjects requiring tacrolimus dose adjustment of tacrolimus for reasons other than optimum C 0 levels. (eg BK Virus Cytomegalovirus Infection)
- •Patients requiring cessation of tacrolimus therapy due to primary graft non-function graft nephrectomy
- •ABO incompatible transplant
- •Patient with positive Donor Specific Antibodies with or without desensitization and panel reactive antibody > 50%
- •Patients >60 years with cognitive impairment (as assessed by a neurologist) will be excluded from the study
- •Patients [deemed by the investigator] to have data on records incomplete to fulfil the study objectives
研究者
相似试验
已完成
不适用
Healthy Volunteer CYP3A5 Genotype studyCTRI/2018/10/016104ithya Gogtay400
进行中（未招募）
1 期
The influence of CYP3A5 and ABCB1 genotype on the pharmacokinetics of twice daily Tacrolimus and Advagraf - Pharmacogenetics of twice daily Tacrolimus and AdvagrafRenal transplantation.MedDRA version: 14.1 Level: LLT Classification code 10023438 Term: Kidney transplant System Organ Class: 100000004865EUCTR2009-013461-25-GBSt. George's, University of London330
Enrolling By Invitation
不适用
Impact of CYP3A5 polymorphisms on intra-patient variability of tacrolimus pharmacokinetics in kidney transplant recipientsage over 18 years old,received immunosuppressive therapy based on twice-daily tacrolimus (Prograf®)tacrolimuspharmacokineticsintrapatient variabilityCYP3A5TCTR20180619003Chulalongkorn University200
已完成
不适用
Impact of POR*28 and CYP3A5 polymorphisms on trough concentration to dose ratio of tacrolimus in Thai kidney transplant recipientskidney transplantationCYP3A5,kidney transplant,pharmacokinetic,pharmacogenetic,POR*28,tacrolimusTCTR20170227005Assoc. Prof. Dr. Atiporn Ingsathit200
已完成
不适用
Studying the relationship between the CYP3A and CYP2D6 probe dextromethorphan and the pharmackinetics of tamoxifen.10006291breast cancerNL-OMON33769Erasmus MC, Universitair Medisch Centrum Rotterdam37